Melasma HQ Cream is a topical medication used to lighten hyperpigmented skin patches, commonly seen in melasma, age spots, and other forms of skin discoloration. It typically contains hydroquinone, a skin-bleaching agent that reduces the production of melanin, the pigment responsible for dark spots. The cream is often part of a treatment regimen aimed at evening skin tone and improving the appearance of darkened areas.

Hydroquinone, the active ingredient in Melasma HQ Cream, works by inhibiting the enzyme tyrosinase, which is essential in the synthesis of melanin.This helps to reduce visible dark spots and promote a more uniform skin tone over time.

Contraindications & Precautions
Melasma HQ Cream should not be used by individuals with a known hypersensitivity to hydroquinone or any other component of the formulation. It is contraindicated on broken, irritated, or infected skin. Prolonged use should be avoided to minimize the risk of ochronosis, a rare condition causing bluish-black discoloration of the skin. Sun exposure should be limited during treatment, and sunscreen is recommended to prevent further pigmentation.

Adverse Reactions / Side Effects
Common side effects include mild skin irritation, redness, dryness, or burning sensation at the application site. Rarely, allergic contact dermatitis may occur. . Patients should discontinue use if severe irritation or allergic reactions develop and consult their healthcare provider.

Pregnancy & Breastfeeding
The safety of Melasma HQ Cream during pregnancy and breastfeeding has not been well established. Due to limited data, its use is generally not recommended during these periods unless prescribed by a healthcare professional after assessing the potential risks and benefits.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Vesanoid (tretinoin) capsules package insert. Nutley, NJ: Roche Laboratories Inc.; 2004 Oct.
2. Auron M, Raissouni N. Adrenal insufficiency. Pediatr Rev 2015;36:92-102.
3. Burns CM. The History of Cortisone Discovery and Development. Rheum Dis Clin North Am. 2016;42:1-14. Review.
4. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2020. Available from: http://www.ginasthma.org.– LinkOpens in New Tab Accessed May 20th, 2020.
5. Das A and Panda S. Use of topical corticosteroids in dermatology: an evidence-based approach. Indian J Dermatol. 2017;62(3):237-50.
6. Fisher GJ, Wang Z, Datta SC, et al. Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med 1997;337:1419-28.
7. Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994;83:10-25.
8. Nu-derm (hydroquinone) cream package insert. Long Beach, CA: OMP, Inc.; 2012 Sep.
9. Briggs GG, Freeman RK, Yaffee SJ. Hydroquinone. In: Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 9th ed. Philadelphia: Lippincott Williams & Wilkins: 2011;700-1.
10. Altreno (tretinoin lotion) package insert; Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2018 Aug.
11. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002;25:345-72.
12. Locoid (hydrocortisone butyrate lotion) package insert. Crawford, NJ: Triax Pharmaceuticals; 2008 Jan.
13. Solu-Cortef (hydrocortisone sodium succinate) injection package insert. New York, NY: Pharmacia and Upjohn Co.; 2019 Nov.
14. Kamm GL, Hagmeyer KO. Allergic-type reactions to corticosteroids. Ann Pharmacother 1999;33(4):451-460.
15. Butani L. Corticosteroid-induced hypersensitivity reactions. Ann Allergy Asthma Immunol 2002;89(5):439-445.
16. Hydrocortone (hydrocortisone sodium phosphate) injection package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2001 Nov.
17. Hydrocortisone 2.5% cream and ointment package insert. Bronx, NY: Perrigo; 2012 Dec.
18. Cortef (hydrocortisone tablets, USP) package insert. New York, NY: Pharmacia & Upjohn Co., Inc.; 2019 Nov.
19. Tretinoin capsules package insert. Sellersville, PA: Teva Pharmaceuticals; 2009 Jun.
20. Retin-A Micro (tretinoin gel) package insert. Quebec, Canada: Valeant Pharmaceuticals North America, LLC; 2017 Oct.
21. Solu-cortef (hydrocortisone sodium succinate) injection package insert. New York, NY: Pharmacia & Upjohn Co.; 2019 Nov.
22. Anusol HC (hydrocortisone acetate) suppository package insert. Morrisville, NC: Salix Pharmaceuticals, Inc.; 2005 Mar.
23. Cortenema (hydrocortisone retention enema) package insert. Baltimore, MD. ANI Pharmaceuticals, Inc.; 2007 Sept.
24. Hydrocortisone 1% cream package insert. Melville, NY: E. Fougera & Co.; 2006 Jun.
25. Hydrocortisone valerate 0.2% cream and ointment package insert. Haethorne, NY: Taro Pharmaceuticals USA, Inc; 2015 Oct.
26. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70:401.e1-14. Review.
27. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.
28. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70:417.e1-10. Review.
29. Tretinoin capsules package insert. Chestnut Ridge, NY: Par Pharmaceutical; 2017 Jan
30. Renova 0.02% (tretinoin cream) package insert; Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2013 Jun.
31. M. Nakagawa, K. Kawai, K. Kawa Contact allergy to kojic acid in skin care products Contact Derm., 32 (1) (1995), pp. 9-13
32. Schimmer B, Parker K. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Molinoff PB, et al., eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 10th edition. New York: McGraw Hill, 2001;1649-1674.
33. Abramson N, Melton B. Leukocytosis: basic of clinical assessment. Am Fam Physician 2000;62:2053-60.
34. Shoenfeld Y, Gurewich Y, Gallant LA, et al. Prednisone-induced leukocytosis. Influenced of dosage, method and duration of administration on the degree of leukocytosis. Am J Med 1981;71:773-8.
35. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994;236:619-32.
36. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
37. Cumming RG, Mitchell P, Leeder SR, et al. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.